Toward Precision Psychedelic Therapies: Chemical, Computational, and Neuromodulatory Innovations.
ACS Med Chem Lett October 9, 2025 DOI: 10.1021/acsmedchemlett.5c00597 via PubMed
Summary
AI-generated from the abstractRecent patents describe complementary strategies to improve psychedelic-assisted therapy. Novel psilocin prodrugs offer better pharmacokinetics and stability, while digital systems allow monitoring of cognitive states during treatment. Parallel developments combine neuroplastogen drugs with transcranial electrical stimulation, using a model-driven approach to enhance and personalize neural plasticity. These innovations together suggest a precision framework for treating neuropsychiatric disorders.
Study at a glance
| Characteristics | Review Peer reviewed |
|---|---|
| Intervention | Psilocin prodrugs |
| Key finding | Recent patents describe complementary strategies—novel psilocin prodrugs, digital cognitive state monitoring, and combining neuroplastogen drugs with transcranial electrical stimulation—that converge on a precision framework for treating neuropsychiatric disorders. |
Abstract
Recent patents disclose complementary strategies to optimize psychedelic-assisted therapy. Novel psilocin prodrugs improve pharmacokinetics and stability, while digital systems enable cognitive state monitoring during treatment. Parallel advances in combining neuroplastogen drugs with transcranial electrical stimulation highlight a model-driven approach to enhance and personalize neural plasticity. Together, these innovations converge on a precision framework for treating neuropsychiatric disorders.